
Sanjay K Murthy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2456156/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Past and Future Burden of Inflammatory Bowel Diseases Based on Modeling of Population-Based Data. Gastroenterology, 2019, 156, 1345-1353.e4.	1.3	273
2	Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study. Gut, 2020, 69, 274-282.	12.1	145
3	AGA Clinical Practice Update on Endoscopic Surveillance and Management of Colorectal Dysplasia in Inflammatory Bowel Diseases: Expert Review. Gastroenterology, 2021, 161, 1043-1051.e4.	1.3	102
4	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Inflammatory Bowel Diseases, 2019, 25, 1-13.	1.9	73
5	The Impact of Inflammatory Bowel Disease in Canada 2018: Direct Costs and Health Services Utilization. Journal of the Canadian Association of Gastroenterology, 2019, 2, S17-S33.	0.3	63
6	Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study. Clinical Epidemiology, 2018, Volume 10, 1613-1626.	3.0	48
7	Longitudinal Trends in the Direct Costs and Health Care Utilization Ascribable to Inflammatory Bowel Disease in the Biologic Era: Results From a Canadian Population–Based Analysis. American Journal of Gastroenterology, 2020, 115, 128-137.	0.4	39
8	Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications. Journal of Crohn's and Colitis, 2020, 14, 1354-1363.	1.3	38
9	Risk of Venous Thromboembolism After Hospital Discharge in Patients With Inflammatory Bowel Disease: A Population-based Study. Inflammatory Bowel Diseases, 2020, 26, 1761-1768.	1.9	35
10	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Clinical Gastroenterology and Hepatology, 2019, 17, 1680-1713.	4.4	32
11	Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease. Journal of the Canadian Association of Gastroenterology, 2019, 2, e1-e34.	0.3	32
12	The Effect of Initiation of Anti-TNF Therapy on the Subsequent Direct Health Care Costs of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2019, 25, 1718-1728.	1.9	31
13	The Impact of Clostridium difficile Infection on Mortality in Patients With Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2019, 53, 127-133.	2.2	26
14	Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 2090-2096.	1.9	25
15	Health Care Utilization and Costs for Patients With End-Stage Liver Disease Are Significantly Higher at the End of Life Compared to Those of Other Decedents. Clinical Gastroenterology and Hepatology, 2019, 17, 2339-2346.e1.	4.4	24
16	Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2019, 17, 1788-1798.e2.	4.4	23
17	Temporal trends in postcolonoscopy colorectal cancer rates inÂ50- to 74-year-old persons: a population-based study. Gastrointestinal Endoscopy, 2018, 87, 1324-1334.e4.	1.0	17
18	Perspectives on endoscopic surveillance of dysplasia in inflammatory bowel disease: a survey of academic gastroenterologists. Endoscopy International Open, 2017, 05, E974-E979.	1.8	15

SANJAY K MURTHY

#	Article	IF	CITATIONS
19	Earlier Anti-TNF Initiation Leads to Long-term Lower Health Care Utilization in Crohn's Disease but Not in Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, 2607-2618.e14.	4.4	13
20	Trends in Corticosteroid Use During the Era of Biologic Therapy: A Population-Based Analysis. American Journal of Gastroenterology, 2021, 116, 1284-1293.	0.4	12
21	Association Between Endoscopist Specialty and Colonoscopy Quality: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2022, 20, 1931-1946.	4.4	12
22	Clinical Practice Guideline for the Medical Management of Perianal Fistulizing Crohn's Disease: The Toronto Consensus. Journal of the Canadian Association of Gastroenterology, 2018, 1, 141-154.	0.3	10
23	Variation in care of patients with elderly-onset inflammatory bowel disease in Ontario, Canada: A population-based cohort study. Journal of the Canadian Association of Gastroenterology, 2021, 4, e16-e30.	0.3	10
24	Shifting Health Care Use from Hospitalisations and Surgeries to Outpatient Visits in Children with Inflammatory Bowel Disease: A Population-based Cohort Study from Ontario, Canada. Journal of Crohn's and Colitis, 2021, 15, 1991-2000.	1.3	10
25	Variable Endoscopist performance in proximal and distal adenoma detection during colonoscopy: a retrospective cohort study. BMC Gastroenterology, 2018, 18, 73.	2.0	9
26	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and Recommendations. Journal of the Canadian Association of Gastroenterology, 2021, 4, S54-S60.	0.3	9
27	Surgery and the Subtype of Inflammatory Bowel Disease Impact the Risk of Venous Thromboembolism After Hospital Discharge. Digestive Diseases and Sciences, 2022, 67, 2471-2479.	2.3	9
28	Venous thromboembolic events in inflammatory bowel diseases: A review of current evidence and guidance on risk in the post-hospitalization setting. Thrombosis Research, 2020, 194, 26-32.	1.7	8
29	High end of life health care costs and hospitalization burden in inflammatory bowel disease patients: A population-based study. PLoS ONE, 2017, 12, e0177211.	2.5	8
30	Appropriateness of Biologics in the Management of Crohn's Disease Using RAND/UCLA Appropriateness Methodology. Inflammatory Bowel Diseases, 2019, 25, 328-335.	1.9	7
31	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Health Care Delivery During the Pandemic and the Future Model of Inflammatory Bowel Disease Care. Journal of the Canadian Association of Gastroenterology, 2021, 4, S61-S67.	0.3	7
32	Tumor Necrosis Factor Inhibitors May Have Limited Efficacy for Complex Perianal Fistulas Without Luminal Crohn's Disease. Digestive Diseases and Sciences, 2020, 65, 1784-1789.	2.3	6
33	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S1-S9.	0.3	5
34	Providing Hospitalized Ulcerative Colitis Patients With Practice Guidelines Improves Patient-Reported Outcomes. Journal of the Canadian Association of Gastroenterology, 2020, 4, 131-136.	0.3	4
35	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S40-S45.	0.3	4
36	An Unusual Skin Manifestation in a Patient With UlcerativeÂColitis. Clinical Gastroenterology and Hepatology, 2016, 14, A35-A36.	4.4	3

SANJAY K MURTHY

#	Article	IF	CITATIONS
37	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S27-S33.	0.3	3
38	Increased Risk of Venous Thromboembolic Events With Corticosteroid Versus Biologic Therapy for Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 166-167.	4.4	2
39	Predictive models of disease burden at diagnosis in persons with adult-onset ulcerative colitis using health administrative data. BMC Gastroenterology, 2019, 19, 13.	2.0	2
40	Absence of Day 3 Steroid Response Predicts Colitis-Related Complications and Colectomy in Hospitalized Ulcerative Colitis Patients. Journal of the Canadian Association of Gastroenterology, 2020, 3, 169-176.	0.3	2
41	Crohn's and Colitis Canada's 2021 Impact of COVID-19 & Inflammatory Bowel Disease in Canada: A Knowledge Translation Strategy. Journal of the Canadian Association of Gastroenterology, 2021, 4, S10-S19.	0.3	2
42	Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Seniors With IBD. Journal of the Canadian Association of Gastroenterology, 2021, 4, S34-S39.	0.3	2
43	Home parenteral nutrition patients on mixed oil lipid emulsion have a higher rate of hospitalizations compare to those on soybean oil– a prospective 2-year cohort study. Clinical Nutrition, 2021, 40, 4616-4623.	5.0	1
44	OUP accepted manuscript. Journal of the Canadian Association of Gastroenterology, 2021, 4, S20-S26.	0.3	0
45	Vedolizumab treatment across antiretroviral treatment interruption in chronic HIV infection: the HAVARTI protocol for a pilot dose-ranging clinical trial to assess safety, tolerance, immunological and virological activity. BMJ Open, 2020, 10, e041359.	1.9	0
46	Multivariable models for advanced colorectal neoplasms in screen-eligible individuals at low-to-moderate risk of colorectal cancer: towards improving colonoscopy prioritization. BMC Gastroenterology, 2021, 21, 383.	2.0	0